Cargando…

Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy.

Carbogen and nicotinamide have been evaluated in a phase II study as hypoxia-modifying agents during radical radiotherapy for bladder cancer using a standard daily 20-fraction schedule. Three groups of patients have received (a) nicotinamide alone, given orally in a dose of 80 mg kg(-1) daily with 5...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoskin, P. J., Saunders, M. I., Phillips, H., Cladd, H., Powell, M. E., Goodchild, K., Stratford, M. R., Rojas, A.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1997
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2223941/
https://www.ncbi.nlm.nih.gov/pubmed/9231929
_version_ 1782149454111965184
author Hoskin, P. J.
Saunders, M. I.
Phillips, H.
Cladd, H.
Powell, M. E.
Goodchild, K.
Stratford, M. R.
Rojas, A.
author_facet Hoskin, P. J.
Saunders, M. I.
Phillips, H.
Cladd, H.
Powell, M. E.
Goodchild, K.
Stratford, M. R.
Rojas, A.
author_sort Hoskin, P. J.
collection PubMed
description Carbogen and nicotinamide have been evaluated in a phase II study as hypoxia-modifying agents during radical radiotherapy for bladder cancer using a standard daily 20-fraction schedule. Three groups of patients have received (a) nicotinamide alone, given orally in a dose of 80 mg kg(-1) daily with 52.5 Gy in 20 fractions over 4 weeks, (b) carbogen alone, with 50 Gy in 20 fractions over 4 weeks, and (c) carbogen and nicotinamide, with 50-52.5 Gy in 20 fractions over 4 weeks. Ten patients were treated in each group. All patients completed carbogen and radiotherapy as prescribed, but only 45% completed daily nicotinamide over the 4-week treatment period. The end points of this study were acute bowel and bladder morbidity and local control at cystoscopy 6 months after treatment. An expected level of acute bowel and bladder morbidity was seen that reverted to normal in most patients by 12 weeks with no difference between the three treatment groups. Complete response rates at 6 months were seven out of ten (100%) in the nicotinamide alone group, nine out of ten (90%) in the carbogen alone group and seven out of ten (70%) in the carbogen and nicotinamide group. It is concluded that carbogen and nicotinamide may improve the results of daily fractionated radiotherapy in bladder cancer and that further evaluation is required.
format Text
id pubmed-2223941
institution National Center for Biotechnology Information
language English
publishDate 1997
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-22239412009-09-10 Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy. Hoskin, P. J. Saunders, M. I. Phillips, H. Cladd, H. Powell, M. E. Goodchild, K. Stratford, M. R. Rojas, A. Br J Cancer Research Article Carbogen and nicotinamide have been evaluated in a phase II study as hypoxia-modifying agents during radical radiotherapy for bladder cancer using a standard daily 20-fraction schedule. Three groups of patients have received (a) nicotinamide alone, given orally in a dose of 80 mg kg(-1) daily with 52.5 Gy in 20 fractions over 4 weeks, (b) carbogen alone, with 50 Gy in 20 fractions over 4 weeks, and (c) carbogen and nicotinamide, with 50-52.5 Gy in 20 fractions over 4 weeks. Ten patients were treated in each group. All patients completed carbogen and radiotherapy as prescribed, but only 45% completed daily nicotinamide over the 4-week treatment period. The end points of this study were acute bowel and bladder morbidity and local control at cystoscopy 6 months after treatment. An expected level of acute bowel and bladder morbidity was seen that reverted to normal in most patients by 12 weeks with no difference between the three treatment groups. Complete response rates at 6 months were seven out of ten (100%) in the nicotinamide alone group, nine out of ten (90%) in the carbogen alone group and seven out of ten (70%) in the carbogen and nicotinamide group. It is concluded that carbogen and nicotinamide may improve the results of daily fractionated radiotherapy in bladder cancer and that further evaluation is required. Nature Publishing Group 1997 /pmc/articles/PMC2223941/ /pubmed/9231929 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Hoskin, P. J.
Saunders, M. I.
Phillips, H.
Cladd, H.
Powell, M. E.
Goodchild, K.
Stratford, M. R.
Rojas, A.
Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy.
title Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy.
title_full Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy.
title_fullStr Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy.
title_full_unstemmed Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy.
title_short Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy.
title_sort carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2223941/
https://www.ncbi.nlm.nih.gov/pubmed/9231929
work_keys_str_mv AT hoskinpj carbogenandnicotinamideinthetreatmentofbladdercancerwithradicalradiotherapy
AT saundersmi carbogenandnicotinamideinthetreatmentofbladdercancerwithradicalradiotherapy
AT phillipsh carbogenandnicotinamideinthetreatmentofbladdercancerwithradicalradiotherapy
AT claddh carbogenandnicotinamideinthetreatmentofbladdercancerwithradicalradiotherapy
AT powellme carbogenandnicotinamideinthetreatmentofbladdercancerwithradicalradiotherapy
AT goodchildk carbogenandnicotinamideinthetreatmentofbladdercancerwithradicalradiotherapy
AT stratfordmr carbogenandnicotinamideinthetreatmentofbladdercancerwithradicalradiotherapy
AT rojasa carbogenandnicotinamideinthetreatmentofbladdercancerwithradicalradiotherapy